Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.52 USD
Change Today -0.10 / -2.16%
Volume 1.4M
SQNM On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (SQNM) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/23/15 - $4.67
52 Week Low
05/1/14 - $2.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SEQUENOM INC (SQNM)

sequenom inc (SQNM) Related Businessweek News

View More BusinessWeek News

sequenom inc (SQNM) Details

Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women's health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample. It also offers a microarray test that uses fetal samples obtained by amniocentesis or chorionic villus sampling under the NextView brand; additional carrier screening tests for Ashkenazi Jewish disorders, spinal muscular atrophy, and fragile X syndrome under the HerediT brand; and RetnaGene age-related macular degeneration (AMD) test to predict the risk of a patient with dry or early stage AMD progressing to wet or advanced choroidal neovascular disease within 2, 5, and 10 years. The company serves physicians and client laboratories. The company was founded in 1994 and is headquartered in San Diego, California.

448 Employees
Last Reported Date: 03/10/15
Founded in 1994

sequenom inc (SQNM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $400.0K
Chief Scientific & Strategy Officer, Executiv...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2013.

sequenom inc (SQNM) Key Developments

Sequenom Inc. Announces Board Changes

Sequenom Inc. announced that its board of directors elected Kenneth Buechler as chairman of the board, effective April 1, 2015. Dr. Buechler succeeds Harry Hixson, who will retire from the position effective March 31, 2015, after 11 years of service. Incoming chairman, Dr. Buechler, has served on the board of directors since December 2009. Prior to joining Sequenom's board, he served as president and chief scientific officer of Biosite Incorporated.

Sequenom Inc. Announces Board Changes, Effective April 1, 2015

Sequenom Inc. Board of Directors elected Dirk van den Boom, Ph.D., current Executive Vice President, Chief Scientific and Strategy Officer, as a director, effective April 1, 2015. In addition, the Board of Directors appointed Dr. van den Boom to the Science Committee of its Board of Directors, also effective April 1, 2015. Dr. van den Boom will fill the vacancy created by the resignation of Harry F. Hixson, Jr., Ph.D. as a director, which resignation is effective March 31, 2015.

Sequenom Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Sequenom Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $36.8 million, an increase of 13% compared to revenues of $32.7 million for the fourth quarter of 2013. This increase in total revenues is primarily due to a higher volume of MaterniT21 PLUS tests performed. Operating income was $20.0 million as compared to a loss of $19.2 million, for the same period in 2013. Net earnings were $18.3 million or $0.14 per diluted share, as compared to a net loss of $18.9 million, or $0.16 per share, for the same period in 2013. This improvement in net earnings is due to the reduced loss from operations and the gain related to the Illumina transaction. Earnings from continuing operations before income taxes was $17,982,000 compared to loss from continuing operations before income taxes of $21,272,000 a year ago. Income from operations was $16,747,000 compared to loss from continuing operation of $19,722,000 a year ago. For the year, the company’s total revenues were $151.6 million, compared to $119.6 million for the prior year 2013, a 27% increase. Revenues are recorded primarily on a cash basis, with 44% of revenue in the fourth quarter of 2014 accounted for on the accrual basis of accounting. Net earnings were $1.0 million, or $0.01 per share, compared to a net loss of $107.4 million for 2013, or $0.93 per share. Loss from continuing operations before income taxes was $22,040,000 compared to loss from continuing operations before income taxes of $110,920,000 a year ago. Loss from operations was $14,364,000 compared to $109,567,000 a year ago. Net cash used in operating activities was $28,086,000 compared to $88,095,000 a year ago. This reduction in cash used in operating activities is primarily due to the increase in revenue and decrease in operating expenses. Purchases of property, equipment and leasehold improvements were $2,236,000 compared to $12,071,000 a year ago. Payment for the purchase of intangible assets was $9,250,000. Net loss from continuing operations improved by 87% to $14.4 million, or $0.12 per share as compared to $109.6 million, or $0.95 per share for 2013. The improvement in the loss from continuing operations from prior year is due to improved gross margins, reduced operating expenses and a gain on the pooled patents agreement with Illumina.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQNM:US $4.52 USD -0.10

SQNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $21.42 USD -0.06
Cerus Corp $4.79 USD +0.205
Luminex Corp $16.10 USD -0.18
Pacific Biosciences of California Inc $5.76 USD -0.14
STAAR Surgical Co $9.14 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation SQNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.5x
Price/Book NM Not Meaningful
Price/Cash Flow 526.9x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at